Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

September 04, 2015 6:26 AM ET


Company Overview of Applied Genetic Technologies Corporation

Company Overview

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops gene therapy products for inherited orphan ophthalmology diseases in the United States. The company’s lead product candidates in the preclinical stage comprise treatments for X-linked retinoschisis, Congenital Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. It also has completed preclinical proof-of-concept studies, and Phase I and Phase II clinical trials of a treatment for alpha-1 antitrypsin deficiency, an inherited orphan lung disease. In addition, the company has proof-of-concept programs for other eye diseases, such as leber con...

11801 Research Drive

Suite D

Alachua, FL 32615

United States

Founded in 1999

18 Employees





Key Executives for Applied Genetic Technologies Corporation

Chief Executive Officer, President and Director
Age: 54
Total Annual Compensation: $313.9K
Chief Financial Officer
Age: 59
Total Annual Compensation: $175.0K
Chief Medical Officer and Vice President
Age: 68
Total Annual Compensation: $336.2K
Executive Director of Process Development
Age: 42
Total Annual Compensation: $122.4K
Compensation as of Fiscal Year 2014.

Applied Genetic Technologies Corporation Key Developments

Applied Genetic Technologies Corporation Announces Achievement of XLRS Patient Enrollment Milestone in Biogen Collaboration

Applied Genetic Technologies Corporation announced it had met a patient enrollment milestone in the X-Linked Retinoschisis (XLRS) clinical study, which will earn AGTC a $5 million payment from Biogen. AGTC filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in March to conduct a Phase I/II clinical trial of the company's gene therapy product candidate for the treatment of XLRS. Utilizing technology licensed from the University of Florida, AGTC's XLRS product candidate uses an AAV capsid with surface residues that have been specifically engineered for better penetration to the back of the eye. The primary clinical endpoint is safety and the secondary endpoints include assessments of visual acuity, visual field, ERG and optical coherence tomography. The study is expected to enroll a total of 27 patients at four sites and preliminary data from the first cohorts of patients are expected by the end of 2015. This marks the first milestone since AGTC and Biogen announced in July a broad collaboration agreement focused on the development of gene-based therapies for two orphan diseases of the retina and three options for early stage discovery programs in two ophthalmic and one non-ophthalmic condition. Biogen has completed the $124 million equity purchase and up-front payment, following the expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the satisfaction of other customary closing conditions.

Applied Genetic Technologies Corporation Presents at BMO Capital Markets Biotech Corporate Access Day, Jul-28-2015

Applied Genetic Technologies Corporation Presents at BMO Capital Markets Biotech Corporate Access Day, Jul-28-2015 . Venue: Boston, Massachusetts, United States.

Applied Genetic Technologies Corporation Presents at Wedbush PacGrow Healthcare Conference 2015, Aug-12-2015 09:45 AM

Applied Genetic Technologies Corporation Presents at Wedbush PacGrow Healthcare Conference 2015, Aug-12-2015 09:45 AM. Venue: Le Parker Meridian, 119 West 56th Street, New York, NY 10019, United States. Speakers: Susan B. Washer, Chief Executive Officer, President and Director.

Similar Private Companies By Industry

Company Name Region
Seahawk Biosystems Corporation United States
CMC ICOS Biologics Inc. United States
AlphaVax, Inc. United States
UroVention, LLC United States
Padlock Therapeutics, Inc. United States

Recent Private Companies Transactions

Private Placement
July 2, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Applied Genetic Technologies Corporation, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at